GlyTherix's radiotherapy approach combines Lu-177 with an antibody targeting Glypican-1, a protein found in aggressive cancers, to deliver localized radiation while sparing healthy tissue.

China National Nuclear Corporation’s (CNNC) first-ever commercial reactor for the production of isotopes has officially ...

Lutetium Lu 177 dotatate is under clinical development by Advanced Accelerator Applications and currently in Phase II for Small-Cell Lung Cancer.

BRCA- and tumor suppressor gene mutations are associated with worse overall survival among patients receiving lutetium-177 PSMA radioligand therapy for mCRPC. Lutetium-177-PMSA radioligand therapy ...

New nuclear reactor for medical isotope production comes online in east China's Zhejiang (Voice_over) One of China's nuclear ...

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

BWX Technologies, Inc. (NYSE: BWXT) today announced that it has entered into an agreement to acquire Kinectrics, Inc., for ...

The USD525 million acquisition of the Canadian nuclear services company Kinetrics "creates a comprehensive portfolio of ...

This photo taken on Dec. 26, 2024 shows workers adjusting and testing China's first commercial reactor device for the online ...